Show simple item record

dc.contributor.authorAu, H.
dc.contributor.authorEiermann, W.
dc.contributor.authorRobert, N.
dc.contributor.authorPienkowski, T.
dc.contributor.authorCrown, J.
dc.contributor.authorMartin, M.
dc.contributor.authorPawlicki, M.
dc.contributor.authorChan, Arlene
dc.contributor.authorMackey, J.
dc.contributor.authorGlaspy, J.
dc.contributor.authorPintér, T.
dc.contributor.authorLiu, M.
dc.contributor.authorFornander, T.
dc.contributor.authorSehdev, S.
dc.contributor.authorFerrero, J.
dc.contributor.authorBée, V.
dc.contributor.authorSantana, M.
dc.contributor.authorMiller, D.
dc.contributor.authorLalla, D.
dc.contributor.authorSlamon, D.
dc.date.accessioned2017-01-30T11:29:23Z
dc.date.available2017-01-30T11:29:23Z
dc.date.created2015-10-29T04:09:56Z
dc.date.issued2013
dc.identifier.citationAu, H. and Eiermann, W. and Robert, N. and Pienkowski, T. and Crown, J. and Martin, M. and Pawlicki, M. et al. 2013. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study. Oncologist. 18 (7): pp. 812-818.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/12232
dc.identifier.doi10.1634/theoncologist.2013-0091
dc.description.abstract

Background. This study aims to describe and compare health- related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast can-cer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-based regimens alone. Methods. Eligible patients (n = 3,222) were randomly assigned to either four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC-T) or one of two trastu- zumab-containing regimens: adjuvant doxorubicin and cyclophos- phamidefollowed bydocetaxel plustrastuzumabadministeredfor1 year (AC-TH) or six cycles of docetaxel pluscarboplatin combined with trastuzumab administered for 1 year (TCH). The European Or-ganization for Research andTreatment of Cancer (EORTC)Qualityof Life Questionnaire C30 and BR-23 were administered at baseline, thestartofcycle4(mid),andtheendofchemotherapy(EOC),aswell as at 6,12, and 24 months after chemotherapy. Results. Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12- month assessment. Systemic side effect (SE) change scores were significantly improved for TCH-treated patients com-pared with AC->TH and AC-T at EOC, suggesting improved tolerability. Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC-TH regimen, but was otherwise similar between arms. All treatment arms re-covered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and fol-low-up. Conclusion. HRQL outcomes for adjuvant docetaxel and trastu- zumab-based regimens are favorable and support TCH as a more tolerable treatment option. © AlphaMed Press 2013.

dc.publisherAlphaMed Press
dc.titleHealth-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study
dc.typeJournal Article
dcterms.source.volume18
dcterms.source.number7
dcterms.source.startPage812
dcterms.source.endPage818
dcterms.source.issn1083-7159
dcterms.source.titleOncologist
curtin.departmentCentre for Population Health Research
curtin.accessStatusOpen access via publisher


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record